Latigo (LTGO) upsizes IPO to $397.4M, extends cash runway
Latigo Biotherapeutics upsized its IPO to $397.4 million, extending its cash runway into 2029. Phase 2 results for onzotrigine in acute pain were published in NEJM; Phase 3 trials are planned.
Story updates
08:46:05 PM UTC
SquawkNews
Lead candidate onzotrigine delivered strong pivotal trial results for acute pain, with Phase 3 trials and topline data expected in 2027. The company completed a $363.9 million IPO, providing funding into 2029, but will require additional capital for full development and commercialization. Risks inc…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.